McCune-Albright syndrome in adolescence with regular menstrual cycle: A case report and literature review

doi:10.3969/j.issn.1004-583X.2022.05.011

Abstract

Abstract:

Objective To analyze the differences of various drugs in treatment of peripheral precocious puberty, and improve the therapeutic level to McCune-Albright syndrome (MAS). Methods In this article, the data of a MAS child from pediatric vaginal bleeding in infancy to regular menstrual cycle in adolescence and the relevant literatures were retrospectively review, the pros and cons of various drugs in treatment of peripheral precocious puberty were analyzed, aiming to provide reference for pediatric endocrinologists. Results Letrozole was relatively safe by reducing endogenous estrogen during treatment. Conclusion Letrozole seems to be more suitable for the treatment of peripheral precocious puberty in MAS children, but follow-up assessments are essential.

Key words: fibrous dysplasia,polyostotic, menstrual cycle, tamoxifen, danazol, letrozole

CLC Number:

R681

Lian Yihua, Pi Yalei, Zhang Yanan, Zhang Huifeng. McCune-Albright syndrome in adolescence with regular menstrual cycle: A case report and literature review[J]. Clinical Focus, 2022, 37(5): 447-450.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.05.011

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I5/447

Figures/Tables 1

References 19

[1]	张博兴, 吴娟娟, 王玉环, 等. 伴性腺功能减退的McCune-Albright 综合征1例[J]. 疑难病杂志, 2021, 20(11):1161-1162.
[2]	Eugster EA, Rubin SD, Reiter EO, et al. Tamoxifen treatment for precocious puberty in McCune-Albright syndrome: A multicenter trial[J]. J Pediatr, 2003, 143(1): 60-66. doi: 10.1016/S0022-3476(03)00128-8 URL
[3]	易琴, 田凤艳, 魏虹, 等. McCune-Albright综合征1例诊治及基因突变分析[J]. 实用儿科临床杂志, 2010, 25(8): 564-566.
[4]	De GBPC, Kuperman H, Cabral DMH, et al. Tamoxifen improves final height prediction in girls with McCune-Albright syndrome: A long follow-up[J]. Horm Res Paediatr, 2015, 84(3): 184-189. doi: 10.1159/000435881 URL
[5]	Alniaimi F, Lyon C. Tamoxifen-induced hirsutism[J]. J Drugs Dermatol, 2011, 10(7): 799-801. pmid: 21720664
[6]	Kirmizibekmez H, Yesiltepe MR, Dursun F, et al. Tamoxifen-associated hirsutism: An unusual side effect in a 5-year-old girl with McCune-Albright syndrome[J]. J Pediatr Endocrinol Metab, 2015, 28(9-10): 1191-1193.
[7]	许晓燕, 徐克惠. 达那唑对卵巢功能安全性的基础研究[J]. 西部医学, 2009, 21(5): 722-724.
[8]	汤蕊, 张宏誉. 达那唑治疗遗传性血管性水肿的疗效与安全性[J]. 药物不良反应杂志, 2013, 15(4): 198-201.
[9]	高宇, 王淼, 宋小宇, 等. 达那唑联合促性腺激素释放激素类似物治疗特发性中枢性性早熟女童对体质量指数及骨代谢标志物水平的影响[J]. 临床和实验医学杂志, 2018, 17(12): 1296-1299.
[10]	Cho EK, Kim J, Yang A, et al. Clinical and endocrine characteristics and genetic analysis of Korean children with McCune-Albright syndrome: A retrospective cohort study[J]. Orphanet J Rare Dis, 2016, 11(1): 113. doi: 10.1186/s13023-016-0496-x URL
[11]	徐德, 陆文丽, 王雪晴, 等. 来曲唑治疗纤维性骨营养不良综合征女性患儿外周性性早熟疗效观察[J]. 浙江大学学报:医学版, 2020, 49(3): 291-296.
[12]	王洁. 第三代芳香化酶抑制剂治疗女孩外周性性早熟的临床分析[D]. 石家庄: 河北医科大学, 2017.
[13]	Feuillan P, Calis K, Hill S, et al. Letrozole treatment of precocious puberty in girls with the McCune-Albright syndrome: A pilot study[J]. J Clin Endocrinol Metab, 2007, 92(6): 2100-2106. doi: 10.1210/jc.2006-2350 URL
[14]	孔元梅, 陈虹, 梁黎, 等. 芳香化酶抑制剂联合生长激素治疗青春期身材矮小症男性患儿的临床研究[J]. 浙江大学学报:医学版, 2020, 49(3): 283-290.
[15]	隆建萍, 马秀芬, 毛宏岩, 等. 第三代芳香化酶抑制剂辅助治疗绝经后乳腺癌疗效与安全性的Meta分析[J]. 疑难病杂志, 2015, 14(4): 396-401.
[16]	李小乐, 金敏. 观察来曲唑治疗绝经后妇女晚期乳腺癌治疗有效率[J]. 世界最新医学信息文摘(连续型电子期刊), 2020, 20(80): 185-186.
[17]	王春林, 梁黎. 第三代非甾体类芳香化酶抑制剂在儿科内分泌临床应用的再认识[J]. 浙江大学学报:医学版, 2020, 49(3): 275-282.
[18]	张莹, 陈瑞敏, 杨晓红, 等. 重组人生长激素联合来曲唑治疗男性青春期矮小临床分析[J]. 中国实用儿科杂志, 2019, 34(9): 775-779.
[19]	Javaid MK, Boyce A, Appelman DN, et al. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: A consensus statement from the FD/MAS international consortium[J]. Orphanet J Rare Dis, 2019, 14(1): 139. doi: 10.1186/s13023-019-1102-9 URL

时间	年龄 (岁)	左侧卵巢 (mm)	左侧卵巢特征	右侧卵巢 (mm)	右侧卵巢特征	子宫 (mm)	内膜 (mm)
2011-6-11	3.25	未见明显异常	-	48×42囊性团块	-	26×16	6
2011-9-14	3.5	14.9×18.7×7.8	-	34.9×39.5×37.3	23、18 mm暗区	26.6×27.4×17.6	4
2013-6-13	5.25	14.9×15.7×14.5	6.1 mm暗区	15.8×16.1×10.7	-	27.5×28×22.1	3.4
2014-3-17	6	27.7×17.8×16.6	-	24.9×21×16.8	18.1 mm暗区	25.7×32.1×20.5	2.7
2014-4-28	6.1	22.4×15.7×15.8	9.2 mm暗区	16.8×20.5×13	8.1、7.7 mm暗区	25.7×33.2×19.1	1.3
2016-7-8	8.3	26.2×13.4	-	子宫右侧探及73.6×64.3×51.1液性包块,包块内见多条强回声分隔,包块周围似可探及部分卵巢回声		28.7×28×21.3	3.7
2018-4-23	10.1	23.2×16.5×10.2	15.4×17.3×3.8 mm暗区	34.3×23.5×29	13.1、10.7、32.2 mm暗区	24.6×22.1×19.2	2.3
2018-10-1	10.5	31.6×23.1	2/3暗区	40.3×28.7	2/3暗区	26.9×28×28.6	3.4

时间	年龄 (岁)	左侧卵巢 (mm)	左侧卵巢特征	右侧卵巢 (mm)	右侧卵巢特征	子宫 (mm)	内膜 (mm)
2011-6-11	3.25	未见明显异常	-	48×42囊性团块	-	26×16	6
2011-9-14	3.5	14.9×18.7×7.8	-	34.9×39.5×37.3	23、18 mm暗区	26.6×27.4×17.6	4
2013-6-13	5.25	14.9×15.7×14.5	6.1 mm暗区	15.8×16.1×10.7	-	27.5×28×22.1	3.4
2014-3-17	6	27.7×17.8×16.6	-	24.9×21×16.8	18.1 mm暗区	25.7×32.1×20.5	2.7
2014-4-28	6.1	22.4×15.7×15.8	9.2 mm暗区	16.8×20.5×13	8.1、7.7 mm暗区	25.7×33.2×19.1	1.3
2016-7-8	8.3	26.2×13.4	-	子宫右侧探及73.6×64.3×51.1液性包块,包块内见多条强回声分隔,包块周围似可探及部分卵巢回声		28.7×28×21.3	3.7
2018-4-23	10.1	23.2×16.5×10.2	15.4×17.3×3.8 mm暗区	34.3×23.5×29	13.1、10.7、32.2 mm暗区	24.6×22.1×19.2	2.3
2018-10-1	10.5	31.6×23.1	2/3暗区	40.3×28.7	2/3暗区	26.9×28×28.6	3.4